Femasys price target raised to $12 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Femasys to $12 from $10 and keeps a Buy rating on the shares following the Q4 report. The analyst says the FemaSeed pivotal data announced recently could boost the initial launch expected in the first half of 2024. The firm sees potential for high uptake following the positive pivotal data results, saying they show validation of higher pregnancy rates that could be obtained with FemaSeed relative to IUI, which is standard first-line treatment.